ArticleScience translational medicine2019
Tuberculosis following PD-1 blockade for cancer immunotherapy.
Open access · greenAbstract readCase Reports
In one paragraph
Article in Science translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 5 pooled it
13.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 5 syntheses or guidelines pooled it, 193 citations in OpenAlex.
- The immunoregulatory landscape of human tuberculosis granulomas.Nature immunology · 2022Pooled it
- Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.Targeted oncology · 2021Pooled it
- Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer.European respiratory review : an official journal of the European Respiratory Society · 2019Pooled it
- Efficacy and tolerability of immunotherapy in advanced nasopharyngeal carcinoma with or without chemotherapy: a meta-analysis.Brazilian journal of otorhinolaryngologyPooled it
- Exacerbation of CMV and Nontuberculous Mycobacterial Infections Following PD-1 Blockade for HIV-Associated Kaposi Sarcoma.Open forum infectious diseases · 2024Trial
- An Update of Cutaneous Melanoma Patients Treated in Adjuvancy With the Allogeneic Melanoma Vaccine VACCIMEL and Presentation of a Selected Case Report With In-Transit Metastases.Frontiers in immunology · 2022Trial
- Host-pathogen interactions in tuberculosis: from immunological mechanisms to translational applications.Cell insight · 2026Review
- Single-cell transcriptomics reveal PD-1-loss-driven immune dysregulation of pulmonary lymphocytes during earlyMicrobiology spectrum · 2026Article
- The impact of immune checkpoint inhibitors on infection in patients with solid malignancies: a systematic review and meta-analysis of randomised controlled trials.EClinicalMedicine · 2026Article
- Divergent macrophage-regulated T cell states determine response to Bacillus Calmette-Guérin vaccine in high-risk bladder cancer.The Journal of clinical investigation · 2026Article
- The host immune response to Mycobacterium tuberculosis determining protection or disease progression.Nature immunology · 2026Review
- Lipid accumulation in tuberculosis granulomas inhibits macrophage-CD4Nature microbiology · 2026Article
- Context-specific roles for IL-17 in tuberculosis.PLoS pathogens · 2026Review
- Targeting Tryptophan Metabolism for Tuberculosis Biomarkers and Host-Directed Therapy.The Journal of infectious diseases · 2026Review
- Immunotherapy for Melanoma in Patients with Altered Immune Systems: Unique Challenges and Clinical Considerations.Advances in therapy · 2026Review
- Advanced immunotherapy across diseases and the role of artificial intelligence: A review.Biomolecules & biomedicine · 2026Review
- Mycobacterium avium infection induced PD-L1 overexpression in macrophages: a potential involvement with immune escape.Cell death & disease · 2026Article
- AFrontiers in tuberculosis · 2026Article
- Case Report: PD-1/CTLA-4 dual checkpoint blockade(QL1706) in advanced pulmonary squamous cell carcinoma complicated by multidrug-resistant tuberculosis after multiple lines of immunotherapy.Frontiers in oncology · 2026Review
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 2 countries.
Daniel L BarberT Lymphocyte Biology Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA. barberd@niaid.nih.gov sharone@mail.nih.gov.ORCID 0000-0003-0344-9447
Shunsuke SakaiT Lymphocyte Biology Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.ORCID 0000-0003-0344-9447
Ragini R KudchadkarDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.
Steven P FlingVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Tracey A DayClinical Immunology Group, Infectious Disease Research Institute, Seattle, WA 98102, USA.ORCID 0000-0003-3771-4309
Julie A VergaraClinical Immunology Group, Infectious Disease Research Institute, Seattle, WA 98102, USA.ORCID 0000-0002-1861-695X
David AshkinDivision of Infectious Diseases and Global Medicine, University of Florida College of Medicine, Gainesville, FL 32610, USA.ORCID 0000-0001-5091-8969
Jonathan H ChengNorris Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.
Lisa M LundgrenCancer Immunotherapy Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0001-9305-9738
Vanessa N RaabeDivision of Infectious Diseases, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0003-2579-1104
Colleen S KraftDepartment of Pathology and Laboratory Medicine, Emory University Hospital, Atlanta, GA 30322, USA.
Jorge J NievaNorris Cancer Center, University of Southern California, Los Angeles, CA 90033, USA.ORCID 0000-0003-1605-4719
Martin A CheeverVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0002-6892-4141
Paul T NghiemDivision of Dermatology, Department of Medicine, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0003-2784-963X
Elad SharonCancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA. barberd@niaid.nih.gov sharone@mail.nih.gov.ORCID 0000-0002-0044-9719
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAEmory University · USInfectious Disease Research Institute · USNational Institute of Allergy and Infectious Diseases · USUniversity of Southern California · USEmory University Hospital · USNational Cancer Institute · USUniversity of Florida · USUniversity of Washington · US
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4MUSC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4MWinship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5MCancer Immunotherapy Trials Network Central Operations and Statistical CenterUM1CA154967 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DAVIDSON, NANCY ELLEN · 2017 to 2022
$20.7MPhase I Molecular and Clinical Pharmacodynamic Trials ETCTNUM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI A. Dimitrios Colevas, Alexey V. Danilov · 2014 to 2026
$19.8MCancer Immunotherapy Trials Network Central Operations and Statistical CenterU01CA154967 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI CHEEVER, MARTIN ALEXANDER · 2010 to 2017
$16.8MImmune Regulation in Mycobacterial InfectionsZIAAI001171 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BARBER, DANIEL · 2012 to 2025
$16.7MTraining a New Generation of VaccinologistsT32AI074492 · NIAID · EMORY UNIVERSITY · PI Rama Rao Amara, Benjamin A Lopman · 2009 to 2026
$6.4MPathogenetic and prognostic studies for improved therapy of Merkel cell carcinomaK24CA139052 · NCI · UNIVERSITY OF WASHINGTON · PI NGHIEM, PAUL · 2009 to 2018
$1.8MHumoral and cellular immunity in polyomavirus-linked Merkel cell carcinomaR01CA162522 · NCI · UNIVERSITY OF WASHINGTON · PI NGHIEM, PAUL · 2011 to 2015
$1.6MNCI NIH HHS K24 CA139052NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015704NCI NIH HHS P30 CA138292NCI NIH HHS R01 CA162522NCI NIH HHS U01 CA154967NCI NIH HHS UM1 CA154967NCI NIH HHS UM1 CA186717NIAID NIH HHS T32 AI074492
Abstract
Because of the well-established therapeutic benefit of boosting antitumor responses through blockade of the T cell inhibitory receptor PD-1, it has been proposed that PD-1 blockade could also be useful in infectious disease settings, including
Indexed as
Aged, 80 and overAnimalsAntibodies, Monoclonal, HumanizedCarcinoma, Merkel CellFatal OutcomeGranulomaHumansImmunotherapyMaleMiddle AgedMycobacterium tuberculosisNasopharyngeal NeoplasmsNeoplasmsNivolumabProgrammed Cell Death 1 ReceptorTh1 CellsAntibodies, Monoclonal, HumanizedNivolumabpembrolizumabProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.